Language

English

Publication Date

8-1-2025

Journal

Stroke

DOI

10.1161/STROKEAHA.125.050977

PMID

40421536

PMCID

PMC12407252

PubMedCentral® Posted Date

5-27-2026

PubMedCentral® Full Text Version

Author MSS

Abstract

Background: The SPAN (Stroke Preclinical Assessment Network) is a confirmatory multicenter trial network to test cerebroprotective interventions in experimental acute stroke. In a first-of-its-kind trial, SPAN tested 6 interventions in a rodent model of transient focal ischemic stroke. Here, we report the efficacy of fasudil, an isoform-nonselective rho-associated kinase inhibitor, on primary and secondary outcomes in the SPAN trial.

Methods: Fasudil was administered at 10 mg/kg intraperitoneally every 12 hours for 6 doses starting 5 minutes before reperfusion in a 60-minute endovascular filament middle cerebral artery occlusion model. The active treatment arm (n=345) was compared with the pooled intraperitoneal and intravenous vehicle arms (n=344). In addition to healthy young mice, the trial included aging mice (16±1 months), diet-induced obese mice, and spontaneously hypertensive rats. The a priori fasudil substudy design stipulated the modified corner test performance on day 28 as the primary end point and separate analyses for mice and spontaneously hypertensive rats using the modified intention-to-treat cohort.

Results: Fasudil improved the primary outcome end point in mice (probabilistic index point estimate, 0.57; P=0.022). The effect appeared stronger in aging mice and when ischemia was induced during the active circadian stage. Fasudil did not show any benefit in the spontaneously hypertensive rats. Alternative analyses using the per-protocol population and imputation generally yielded similar conclusions.

Conclusions: Our results reveal a favorable therapeutic profile for fasudil, supporting future translational development of rho-associated kinase inhibitors in ischemic stroke.

Keywords

Animals, Female, Male, Mice, Rats, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine, Brain Ischemia, Disease Models, Animal, Ischemic Stroke, Mice, Inbred C57BL, Protein Kinase Inhibitors, Rats, Inbred SHR, rho-Associated Kinases, Fasudil, focal cerebral ischemia, middle cerebral artery occlusion, mouse, aging, obesity, spontaneously hypertensive rat, preclinical trial

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.